Full-Time

Director of Assay Development and Biomarkers

Posted on 12/10/2025

Korro Bio

Korro Bio

51-200 employees

RNA editing-based therapeutics discovery and development

Compensation Overview

$205k - $246k/yr

+ Equity

Cambridge, MA, USA + 1 more

More locations: Massachusetts, USA

Hybrid

Hybrid role requiring on-site presence at multiple MA locations.

Category
Biology & Biotech (3)
, ,
Required Skills
Pharmacology
Requirements
  • MS or PhD in Molecular Biology, Immunology, Pharmacology, or related life sciences discipline.
  • Therapeutic area experience in Liver Diseases, Neurological Disorders, or Rare Diseases.
  • 10+ years of experience in biomarker research, translational science, or assay development within the biotech/pharma industry.
  • Proven experience with biomarker strategy and assay development across discovery, clinical, and commercial stages.
  • Demonstrated success working with regulatory agencies on biomarker and CDx-related filings.
  • Experience managing CROs and external diagnostic partners.
  • Deep knowledge of a broad range of assay platforms and technologies.
  • Familiarity with GLP/GCLP, CLIA, and regulatory requirements for biomarker assays.
  • Strong understanding of genomics, proteomics, and data integration.
  • Proven leadership in cross-functional matrix environments.
  • Excellent written and verbal communication skills, including scientific presentation and regulatory writing experience.
  • Strategic thinker with operational excellence and scientific rigor.
Responsibilities
  • Develop and execute biomarker strategies aligned with program objectives across all development stages (preclinical, clinical, regulatory, and commercial).
  • Define and prioritize biomarker hypotheses (PD, prognostic, predictive, safety, response) and guide integration into study designs.
  • Provide expert input into translational and clinical development plans, including end-to-end biomarker plans for IND, CTA, and NDA/MAA submissions.
  • Lead the development, optimization, and validation of robust, fit-for-purpose biomarker assays (e.g., IHC, ELISA, PCR, NGS, flow cytometry, mass spectrometry, multiplex platforms).
  • Oversee internal or outsourced assay development and qualification for exploratory clinical trial use (CLIA/CAP, GCLP), and companion diagnostics (IVD).
  • Ensure assay readiness and quality for use in clinical trials (e.g., sample logistics, CRO/vendor oversight, SOPs, assay tech transfer).
  • Partner with scientists, clinical teams, and regulatory leads to integrate biomarkers into clinical trial protocols and endpoints.
  • Monitor biomarker data in ongoing studies; provide real-time interpretation to support clinical decisions.
  • Collaborate with biostatistics, bioinformatics, and data science teams for analysis, interpretation, and visualization of biomarker data.
  • Drive partnerships with discovery, clinical, regulatory, commercial, and CDx development functions to ensure continuity and alignment.
  • Manage external vendors, CROs, and diagnostic partners; serve as technical and scientific lead in biomarker-related interactions.
  • Represent biomarker strategy at governance meetings, scientific advisory boards, and regulatory interactions as needed.
  • Support regulatory filings (e.g., INDs, NDAs, CTDs) with biomarker and assay content, including responses to health authority questions.
  • Develop biomarker plans for post-marketing commitments, real-world evidence generation, or CDx lifecycle management.

Korro Bio develops RNA-based therapies using RNA editing to modify protein function, aiming to treat serious diseases with few or no current options. The approach targets RNA itself, enabling single base edits in transcripts to change how proteins work, which can adjust disease pathways without altering the DNA. These therapies are intended to be developed and brought to market through direct development or partnerships, with revenue coming from therapy sales, licensing, and collaborations. The company focuses on research and development to translate human genetics insights into treatments, working with healthcare providers, patients, and academic partners. Overall, Korro Bio seeks to move RNA editing toward real therapies that can help patients around the world by offering precise, targeted interventions at the RNA level.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • $85M PIPE in 2025 extends cash runway through H2 2028.
  • Novo Nordisk partnership develops cardiometabolic candidates since Sept 2024.
  • KRRO-121 advances for urea cycle disorders and hepatic encephalopathy.

What critics are saying

  • KRRO-110 trial failed functional protein levels, causing 80% stock drop.
  • Beam Therapeutics' base editing outpaces Korro in AATD liver delivery.
  • Intellia CRISPR AATD enters Phase 1 with 50% NHP protein correction.

What makes Korro Bio unique

  • OPERA platform co-opts endogenous ADAR for precise single-base RNA edits.
  • CHORD oligonucleotides enable high specificity without off-target DNA risks.
  • Targets liver diseases like AATD using precedented manufacturing and delivery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

10%

2 year growth

12%
Maeil Business Newspaper
Mar 9th, 2026
Korro Bio raises $85M PIPE to fund operations through H2 2028

Korro Bio has raised $85 million through a private investment in public equity (PIPE) round led by new investor Bainrock Healthcare Capital Partners. The company issued 4.5 million ordinary shares at $11.11 per share and 3.1 million pre-funded warrants at $11.109 per share. Combined with $85.2 million in cash and cash equivalents as of 31 December 2025, the funding extends Korro Bio's cash runway through the second half of 2028. The capital will accelerate development of its RNA editing platform OPERA, including clinical programmes KRRO-121 and a GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency. Citigroup, Cantor, Oppenheimer and William Blair served as placement agents. Analysts forecast continued losses through 2027 despite projected revenue growth.

Investing.com
Mar 9th, 2026
Korro Bio raises $85 million in private equity financing By Investing.com

Korro Bio raises $85 million in private equity financing

Stock Titan
Jan 7th, 2025
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Korro to present at the 43rd Annual J.P. Morgan Healthcare Conference.

Investing.com
Oct 16th, 2024
KRRO stock soars to 52-week high, touches $98 amid robust gains

In other recent news, Korro Bio has announced a strategic partnership with Novo Nordisk (NYSE:NVO), a global healthcare company, to develop genetic medicines for cardiometabolic diseases.

BioSpace
Sep 16th, 2024
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

Korro Bio announces collaboration with Novo Nordisk to develop two therapeutic candidates.

INACTIVE